Syndax Pharmaceuticals, which is developing a therapy that enhances checkpoint immuno-oncology drugs, raised $53 million by offering 4.4 million shares at $12, below the range of $14 to $16. Syndax Pharmaceuticals plans to list on the Nasdaq under the symbol SNDX. Morgan Stanley and Citi acted as lead managers on the deal.
